Talks for the purchase of a potential vaccine against COVID-19 have been concluded between the European Commission and BioNTech-Pfizer on September 9, 2020.
BioNTech-Pfizer is the sixth company with which the European Commission has concluded talks, following Sanofi-GSK, Johnson and Johnson, CureVAc, Moderna and AstraZeneca.
The expected contract would provide for the possibility for all Member States to purchase the vaccine.
It is anticipated that the European Commission will have a framework in place for the initial purchase of 200 million doses, plus an option to purchase up to a further 100 million doses, to be supplied once a vaccine has proven to be safe and effective against COVID-19.
For more information please click here.« Back